Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. - Wikidata - awgldk - TriplyDB

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

http://www.wikidata.org/entity/Q33383459

about

A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma Role of the tumor microenvironment in mature B-cell lymphoid malignancies Lymphoma Immunotherapy: Current Status Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion Management of mantle cell lymphoma in the elderly patient Mantle cell lymphoma: observation to transplantation Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells Novel CD20 monoclonal antibodies for lymphoma therapy Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.A review of the history, properties, and use of the immunomodulatory compound lenalidomide.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.Targeted therapy in lymphoma.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia Novel therapeutics for aggressive non-Hodgkin's lymphoma.Molecular targeted approaches in mantle cell lymphoma.HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma Expanding role of lenalidomide in hematologic malignancies Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.Ongoing trials in low-grade lymphoma Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.

P2860

Q26738937-1CD5AD6B-1E44-4DF9-9857-8F3EE3A0C49E Q26748775-F3565228-5C6E-46B9-A1CD-D2E6636D42EE Q26782902-DFD21EB1-DFC3-43F9-A039-688C5926F7BE Q26783430-A1E7C70D-3E9C-47AC-A2CE-73B39FA97E34 Q26999395-6DB44508-5878-43A1-82A6-6398BFC9146E Q28256317-65E8383D-27A9-4424-8C3F-A95370725488 Q28303091-B103ACC0-7748-422C-8CCB-D1B69B1DA346 Q28390112-922FB687-7E01-4FB0-97D3-96B07086C8FD Q30358639-EF41605D-9A19-4B44-B2B7-CDE72D0B4A75 Q33388648-85313FBB-6A95-4D13-B549-075B56221A17 Q33393623-760B0B86-1D4B-4234-88F4-91345EC50BD5 Q33394623-355EB554-A0AE-4F09-B04F-068DBB9CA877 Q33396036-E519FE60-0D8C-48DB-977C-871F872B07BD Q33398019-2F60E396-89EA-49C0-B478-217EA3377E9B Q33398818-38718CA1-48E1-4903-B649-35BF10A9F934 Q33405103-8A14FBC6-662C-4185-BCE7-CB7A2EAEC1B2 Q33408772-A2782682-C6A9-4946-8373-56928D2D8C8A Q33410282-D09C9B7A-9519-41C1-A1DB-8084BBA4FC0B Q33416695-A453D959-9269-4D2F-BB7A-B80FD97B422E Q33418964-D3CE6CE7-C546-472E-8758-2454C43C3AC4 Q33423873-9659EEAF-5771-4F05-8461-67FB4C804311 Q33586239-C7A1DDDF-5481-4431-A1B2-16D12AE93C56 Q33817800-211C1FA1-21FC-416F-A811-49EFF93BD7A6 Q33832937-30327A90-465B-4D07-8365-4E92DF8B52F1 Q34129360-63B7C729-F9AE-4DB2-A1EC-5567FC401EB3 Q34173071-ABEAEE21-28C9-4F24-8F9C-49DE839837DB Q34220013-BB789A04-019E-4DF2-A5D6-B3368463FE3F Q34253548-7CA5EA28-1082-49D6-A463-62458892F659 Q34365673-B80D6F70-A624-4AA9-9948-FE04975BD486 Q34413686-CCA3ADBB-3795-47F5-B672-E548313CD049 Q34568868-1DBBB1C9-EC15-48D7-BAFD-20074EEAD47B Q34683488-7175A092-CA29-48B3-837E-3468DCDCA633 Q35033519-3FF7235E-EC47-4C81-A292-8940635B9FA6 Q35111768-976F1E08-0E28-4C9B-A89F-46C9AEBC1BE9 Q35127368-9255B4E3-EA4E-4950-9E20-DEE703FF94A6 Q35483623-E17D65F4-6FC9-4CC8-AC5D-D80C86F0FFEC Q35592305-232C35B7-7A92-44FF-9D27-35BA84A3600E Q35629679-8DBDEF38-2FBC-4D30-9CC5-94BE1302E713 Q35715996-D35B1D32-2C4D-458F-A302-B3E3DB0CB09C Q35777792-D8D69A69-F2A3-486D-A6EA-49B7A54DE4CC

P2860

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

http://www.wikidata.org/entity/Q33383459

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.

@ast

Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.

@en

type

label

Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.

@ast

Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.

@en

prefLabel

Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.

@ast

Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.

@en

P1433

Q33383459-7495E8DD-2CCB-4775-8B89-71C28FCAAFA2

P1476

Q33383459-98DEC830-0E96-4A6F-B516-572139380B88

P2093

Q33383459-03ED18FB-EF74-49FB-9E65-7D6242964C21

Q33383459-162988C4-113B-4E0B-A8FF-6C8891721451

Q33383459-21DC8035-6B0D-4C04-ACEB-C079FC5523A8

Q33383459-691C843B-8F98-4E9C-BCC1-62840ED4C7C4

Q33383459-935E7409-D205-4F82-869D-751E76738D9A

Q33383459-A6762A60-14CE-4AA1-8AE2-81A9FA340807

Q33383459-B039A6C5-3CFD-4616-B647-B18167DB18FF

Q33383459-DD827FF7-5DFE-4CB0-A97C-6AD07DE7A07E

Q33383459-E96DAC71-193F-420C-B97C-D3A7CAAE68AA

Q33383459-EEF3DADB-C891-491F-85C0-510E95FBBA33

P304

Q33383459-7B9C5C9A-D465-4C90-8381-7DC881567E6C

P31

Q33383459-9DEF6C7B-9575-488C-98F6-A64A2E89ACE9

P356

Q33383459-5FEE749B-BA2E-4457-8931-CED4CAF0C2F5

P407

Q33383459-A0A85B40-067C-4455-9513-2D4BF34F99DD

P433

Q33383459-742A2482-7C86-4613-B0CA-8CEB59E871CD

P478

Q33383459-90D00F38-7ABB-4CAF-B774-95443102B0F8

P50

Q33383459-2B603FEF-DE7B-445A-82ED-175D57F6966E

P577

Q33383459-2979E4D5-79C3-497D-BFC4-DF18185C88DA

P5875

Q33383459-038639B5-7E4E-407C-A4E7-2197A12B3742

P698

Q33383459-C1879F1C-0C7D-4F7A-BB2A-3CD965F89656

P356

J.1365-2141.2009.07626.X

P1433

British Journal of Haematology

P1476

Lenalidomide oral monotherapy ...... fractory mantle cell lymphoma.

@en

P2093

Annette Ervin-Haynes

http://www.w3.org/2001/XMLSchema#string

Dennis Pietronigro

http://www.w3.org/2001/XMLSchema#string

Glen Justice

http://www.w3.org/2001/XMLSchema#string

Izidore S Lossos

http://www.w3.org/2001/XMLSchema#string

Jerome B Zeldis

http://www.w3.org/2001/XMLSchema#string

Joseph M Tuscano

http://www.w3.org/2001/XMLSchema#string

Kenichi Takeshita

http://www.w3.org/2001/XMLSchema#string

Kenton Wride

http://www.w3.org/2001/XMLSchema#string

Kyle McBride

http://www.w3.org/2001/XMLSchema#string

Peter H Wiernik

http://www.w3.org/2001/XMLSchema#string

P304

344-349

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2009.07626.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

145

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24042706

http://www.w3.org/2001/XMLSchema#string

P698

19245430

http://www.w3.org/2001/XMLSchema#string